VTGN Latest Press Releases

-- November 13, 2026 --

Vistagen Reports Fiscal Year 2027 Second Quarter Financial Results and Provides Corporate Update Globe Newswire 4:05 PM

-- November 9, 2026 --

Vistagen Provides Regulatory Update Following Productive Type C Meeting with U.S. FDA on Phase 3 Development of Fasedienol for Social Anxiety Disorder Globe Newswire 8:30 AM

-- October 20, 2026 --

Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs Globe Newswire 8:30 AM

-- September 24, 2026 --

SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO) Globe Newswire 12:30 PM

Vistagen Reports Positive Findings Supporting Fasedienol's Potential in Very Severe Social Anxiety Disorder Globe Newswire 7:00 AM

-- September 22, 2026 --

Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Globe Newswire 8:30 AM

-- September 10, 2026 --

Vistagen to Present at Psych Congress 2026 Globe Newswire 8:30 AM

-- August 14, 2026 --

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update Globe Newswire 8:32 AM

-- August 6, 2026 --

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder Globe Newswire 8:30 AM

-- August 4, 2026 --

SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN) Globe Newswire 5:00 AM

-- July 31, 2026 --

Vistagen Appoints Douglas J. Williamson to its Board of Directors Globe Newswire 8:30 AM

-- June 30, 2026 --

Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder Business Wire 8:00 AM

-- June 15, 2026 --

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update Business Wire 4:30 PM

Market Data Delayed 15 Minutes